Shandong Lukang Pharmaceutical Co.,Ltd. (SHA:600789)
China · Delayed Price · Currency is CNY 8.16
+0.07 (0.87%)
Apr 29, 2026, 3:00 PM CST
SHA:600789 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,709 | 5,766 | 6,164 | 6,067 | 5,545 | 4,877 |
Other Revenue | - | - | 68.85 | 79.76 | 76.51 | 47.22 |
| 5,709 | 5,766 | 6,233 | 6,147 | 5,621 | 4,924 | |
Revenue Growth (YoY) | -6.54% | -7.49% | 1.41% | 9.34% | 14.17% | 17.09% |
Cost of Revenue | 4,438 | 4,493 | 4,806 | 4,686 | 4,416 | 3,777 |
Gross Profit | 1,271 | 1,273 | 1,427 | 1,461 | 1,206 | 1,147 |
Selling, General & Admin | 699.72 | 710.92 | 802.19 | 810.21 | 688.02 | 675.05 |
Research & Development | 294.63 | 299.15 | 317.15 | 345.79 | 264 | 266.03 |
Other Operating Expenses | -5.87 | -11.94 | -11.81 | 37.65 | 51.16 | 38.04 |
Operating Expenses | 988.47 | 998.13 | 1,110 | 1,195 | 1,012 | 1,004 |
Operating Income | 282.39 | 274.72 | 316.74 | 266.14 | 194.06 | 143.37 |
Interest Expense | - | - | -75.38 | -79.17 | -98.04 | -65.13 |
Interest & Investment Income | - | - | 12.48 | 8.94 | 7.19 | 6.92 |
Currency Exchange Gain (Loss) | - | - | 11.93 | 7.52 | 19.49 | -5.52 |
Other Non Operating Income (Expenses) | -59.7 | -62.66 | -13.8 | -7.22 | -5.85 | -4.63 |
EBT Excluding Unusual Items | 223.98 | 212.06 | 251.97 | 196.2 | 116.85 | 75.02 |
Gain (Loss) on Sale of Investments | -6.5 | -5.29 | -7.56 | -7.2 | -6.53 | -3.18 |
Gain (Loss) on Sale of Assets | 0.14 | 0.17 | 153.42 | 0.28 | 2.65 | -0.38 |
Asset Writedown | -75.71 | -45.73 | -0.15 | - | -0.82 | -0.14 |
Other Unusual Items | - | - | 36.22 | 83.7 | 37.95 | 42.27 |
Pretax Income | 141.92 | 161.21 | 433.9 | 272.98 | 150.1 | 113.58 |
Income Tax Expense | 55.82 | 49.3 | 25.55 | 16.19 | 6.98 | 23.69 |
Earnings From Continuing Operations | 86.09 | 111.91 | 408.35 | 256.79 | 143.11 | 89.89 |
Minority Interest in Earnings | 0.87 | 0.4 | -13.73 | -10.62 | -5.1 | -0.79 |
Net Income | 86.96 | 112.3 | 394.62 | 246.17 | 138.01 | 89.1 |
Net Income to Common | 86.96 | 112.3 | 394.62 | 246.17 | 138.01 | 89.1 |
Net Income Growth | -78.58% | -71.54% | 60.30% | 78.37% | 54.90% | -60.90% |
Shares Outstanding (Basic) | 984 | 936 | 897 | 879 | 863 | 891 |
Shares Outstanding (Diluted) | 984 | 936 | 897 | 879 | 920 | 891 |
Shares Change (YoY) | 8.73% | 4.35% | 2.01% | -4.45% | 3.27% | -2.25% |
EPS (Basic) | 0.09 | 0.12 | 0.44 | 0.28 | 0.16 | 0.10 |
EPS (Diluted) | 0.09 | 0.12 | 0.44 | 0.28 | 0.15 | 0.10 |
EPS Growth | -80.30% | -72.73% | 57.14% | 86.67% | 50.00% | -60.00% |
Free Cash Flow | 503.75 | 359.31 | 123.64 | 266.09 | 16.02 | -311.07 |
Free Cash Flow Per Share | 0.51 | 0.38 | 0.14 | 0.30 | 0.02 | -0.35 |
Dividend Per Share | - | - | 0.132 | 0.090 | 0.050 | 0.050 |
Dividend Growth | - | - | 46.67% | 80.00% | - | -9.09% |
Gross Margin | 22.26% | 22.07% | 22.89% | 23.77% | 21.45% | 23.29% |
Operating Margin | 4.95% | 4.76% | 5.08% | 4.33% | 3.45% | 2.91% |
Profit Margin | 1.52% | 1.95% | 6.33% | 4.00% | 2.46% | 1.81% |
Free Cash Flow Margin | 8.82% | 6.23% | 1.98% | 4.33% | 0.29% | -6.32% |
EBITDA | 743.97 | 723.79 | 715.75 | 647.27 | 542.18 | 450.83 |
EBITDA Margin | 13.03% | 12.55% | 11.48% | 10.53% | 9.64% | 9.16% |
D&A For EBITDA | 461.58 | 449.07 | 399.01 | 381.13 | 348.12 | 307.46 |
EBIT | 282.39 | 274.72 | 316.74 | 266.14 | 194.06 | 143.37 |
EBIT Margin | 4.95% | 4.76% | 5.08% | 4.33% | 3.45% | 2.91% |
Effective Tax Rate | 39.34% | 30.58% | 5.89% | 5.93% | 4.65% | 20.86% |
Revenue as Reported | - | - | 6,233 | 6,147 | 5,621 | 4,924 |
Advertising Expenses | - | - | - | - | - | 259.79 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.